A recent clinical trial finds the anti-parasitic drug moxidectin -- currently approved to treat river blindness, another tropical disease caused by parasitic worms -- is also more effective for lymphatic filariasis than the current gold standard, ivermectin.
Read more …A faster route to eliminating parasitic infection endemic to Africa
Researchers identified a natural 'brake' within the innate immune system: the inhibitory receptor Siglec-E (SigE) and its human counterparts, Siglec-7 and Siglec-9. This receptor helps prevent overactivation of immune cells that drive rejection. When this brake is missing, inflammation worsens, leading to faster rejection in preclinical models. Importantly, transplant patients with higher levels of Siglec-7 and Siglec-9 showed better graft survival, highlighting this pathway as a promising target for new therapies.
Read more …Insights on preventing organ transplant rejection